The notices it replaced
- Reissues: PAR-25-029 Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
- 2 steps back: PAR-22-192 Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
- 3 steps back: PAR-19-329 Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
- 4 steps back: PAR-18-407 Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3) - Clinical Trial Required
- 5 steps back: PAR-16-300 Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3)
Who won it before
53 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $75,754,363 in first-year total cost, median $1,264,646.
Most frequent study sections
- Clinical Trials Review Study Section[CLTR (MA)]18
- Clinical Trials Review Study Section[CLTR (JA)]13
- Clinical Trials Review Study Section[CLTR (OA)]7
- Special Emphasis Panel[ZHL1 CSR-Z (J1)]3
- Special Emphasis Panel[ZHL1 CSR-H (F1)]2
Most frequent institutions
- DUKE UNIVERSITY6
- STANFORD UNIVERSITY4
- JOHNS HOPKINS UNIVERSITY3
- NORTHWESTERN UNIVERSITY AT CHICAGO3
- OHIO STATE UNIVERSITY3
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | (1/2) Statins to Prevent Cancer Associated Venous Thromboembolism (STAT-CAT): CCC1UG3HL176627-01A1 · under PAR-22-192 | CONNORS, JEAN MARIEKHORANA, ALOK ARIDKER, PAUL M. | BRIGHAM AND WOMEN'S HOSPITAL, MA | $2,290,286 | CLTR |
| 2025 | 1/2 A Phase 2 Study of Elafin (Tiprelestat) for the Treatment of Pulmonary Arterial Hypertension (PAH)1UG3HL180990-01 · under PAR-22-192 | RABINOVITCH, MARLENEZAMANIAN, ROHAM | STANFORD UNIVERSITY, CA | $1,998,124 | ZHL1 |
| 2025 | 1/2 WIN Ratio Analysis to Determine a Strategy of Non-Invasive SUpport for Respiratory Failure in the EmeRgency Department (WINDSURFER)1UG3HL175260-01A1 · under PAR-22-192 | MOSIER, JARRODTIDSWELL, MARK AWANG, HENRY E. | OHIO STATE UNIVERSITY, OH | $1,535,439 | ZHL1 |
| 2025 | 1/2 ASTRO: Adjuvant STeRoid Outcomes in idiopathic subglottic stenosis: A randomized trial1UG3HL173394-01A1 · under PAR-22-192 | GELBARD, ALEXANDERHILLEL, ALEXANDER | JOHNS HOPKINS UNIVERSITY, MD | $1,314,743 | CLTR |
| 2025 | 1/2 Women's Aneurysm Research: Repair Immediately Or Routine Surveillance: WARRIORS trial1UG3HL181184-01 · under PAR-22-192 | ARYA, SHIPRA | STANFORD UNIVERSITY, CA | $1,196,948 | CLTR |
| 2025 | 1/2 Randomized comparison of the Outcomes of single vs Multiple Arterial grafts trial in Women (ROMA:Women)1UG3HL169564-01A1 · under PAR-22-192 | BAIREY MERZ, CATHLEEN NOELGAUDINO, MARIO FLMASTERSON CREBER, RUTH MARIE | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $1,048,249 | CLTR |
| 2024 | 1/2 Low dose colchicine in pAtients with peripheral artery DiseasE to assess residual vascular risk (LEADER-PAD)1UG3HL171357-01A1 · under PAR-22-192 | PATEL, MANESH RRYMER, JENNIFER | DUKE UNIVERSITY, NC | $1,858,859 | ZHL1 |
| 2024 | IMProving mobility After revasCularizaTion in Peripheral Artery Disease: the IMPACT PAD Trial1UG3HL169565-01A1 · under PAR-22-192 | MCDERMOTT, MARY MCGRAE | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $1,264,646 | CLTR |
| 2024 | 1/2 Circulatory Support in Pediatric Heart Failure Patients Using the Jarvik 2015 LVAD: A Pivotal Trial1UG3HL163311-01A1 · under PAR-19-329 | ALMOND, CHRISTOPHERDAVIES, RYAN ROBERTMAHLE, WILLIAM T | STANFORD UNIVERSITY, CA | $1,073,956 | ZHL1 |
| 2024 | Inhaled Nitric Oxide for Congenital Diaphragmatic Hernia - The "NONO trial" - a pragmatic, multi-center, de-implementation, stepped-wedge, cluster-randomized trial1UG3HL166767-01A1 · under PAR-22-192 | BLAKELY, MARTIN LEEJANCELEWICZ, TIMOTHY | UNIVERSITY OF TENNESSEE HEALTH SCI CTR, TN | $915,604 | CLTR |
| 2024 | 1/2 Clinical Coordinating Center for the Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction Study (SPIRRIT-EX)1UG3HL173571-01 · under PAR-22-192 | DEVORE, ADAM D | DUKE UNIVERSITY, NC | $877,758 | ZHL1 |
| 2024 | 1/2 Self-directed mobile adaptive coping skills intervention to improve psychological distress symptoms among cardiorespiratory failure survivors: the Blueprint RCT1UG3HL168487-01A1 · under PAR-22-192 | COX, CHRISTOPHER ETHAN | DUKE UNIVERSITY, NC | $820,823 | CLTR |
| 2024 | 1/2 Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension1UG3HL175041-01 · under PAR-22-192 | HERESI DAVILA, GUSTAVO ADOLFO | CLEVELAND CLINIC LERNER COM-CWRU, OH | $433,123 | CLTR |
| 2024 | 1/2 Neonatal Platelet Transfusion Threshold Trial (NeoPlaTT)1UG3HL173303-01 · under PAR-22-192 | PATEL, RAVI MANGALSOLA-VISNER, MARTHA C. | EMORY UNIVERSITY, GA | $359,493 | CLTR |
| 2024 | 1/2 Milrinone for Prevention of Post-Patent Ductus Arteriosus Closure Syndrome in Extremely Preterm Infants (MIDAS Trial) – CCC1UG3HL166579-01A1 · under PAR-22-192 | BELL, EDWARD FMCNAMARA, PATRICK J | UNIVERSITY OF IOWA, IA | $342,731 | CLTR |
| 2023 | 1/2 REPRIEVE Extension for Trial Completion1UG3HL164285-01 · under PAR-19-329 | DOUGLAS, PAMELA SUSANGRINSPOON, STEVEN K. | MASSACHUSETTS GENERAL HOSPITAL, MA | $6,567,877 | ZHL1 |
| 2023 | 1/2 – Pediatric Prehospital Airway Resuscitation Trial1UG3HL165019-01A1 · under PAR-22-192 | WANG, HENRY E. | OHIO STATE UNIVERSITY, OH | $1,902,731 | CLTR |
| 2023 | 1/2 Cognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in Insomnia Phenotypes Based on Objective Sleep Duration: A Sequential Cohort/Randomized Controlled Trial1UG3HL161342-01A1 · under PAR-19-329 | BUYSSE, DANIEL J.FERNANDEZ-MENDOZA, JULIOMORIN, CHARLES M.SMITH, ELIZABETH DEVONTAYLOR COUSAR, JENNIFER LYNNVGONTZAS, ALEXANDROS N | PENNSYLVANIA STATE UNIV HERSHEY MED CTR, PA | $1,851,722 | ZHL1 |
| 2023 | 1/2 Multi-Center CLEAN AIR 2 Randomized Control Trial in COPD1UG3HL169561-01 · under PAR-22-192 | HANSEL, NADIA N | JOHNS HOPKINS UNIVERSITY, MD | $1,826,564 | CLTR |
| 2023 | 1/2 IMPRoving Outcomes in Vascular DisEase - Aortic Dissection (IMPROVE-AD)1UG3HL165017-01A1 · under PAR-19-329 | KOUGIAS, PANAGIOTISMUSSA, FIRAS FUADPATEL, MANESH R | DUKE UNIVERSITY, NC | $1,528,379 | ZHL1 |
| 2023 | 1/2: PREcision VENTilation to attenuate Ventilation-Induced Lung Injury (PREVENT VILI)1UG3HL166785-01A1 · under PAR-22-192 | BEITLER, JEREMY R.TALMOR, DANIEL STUART | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $1,445,727 | CLTR |
| 2023 | 1/2 CORD-CHD: Clamp OR Delay among neonates with Congenital Heart Disease1UG3HL166794-01 · under PAR-19-329 | BACKES, CARLHILL, KEVIN DENNISKATHERIA, ANUP C | RESEARCH INST NATIONWIDE CHILDREN'S HOSP, OH | $907,257 | CLTR |
| 2022 | The Rhythm Evaluation for Anticoagulation with Continuous Monitoring of Atrial Fibrillation Trial (REACT-AF)1UG3HL165065-01 · under PAR-19-329 | PASSMAN, ROD S | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $3,610,112 | CLTR |
| 2022 | 1/2 Pulmonary Embolism: Thrombus Removal with Catheter-Directed Therapy (PE-TRACT Trial)1UG3HL155798-01A1 · under PAR-19-329 | RAO, SUNIL VSISTA, AKHILESH K | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $2,190,267 | CLTR |
| 2022 | 1/2 Trauma Resuscitation with Group O Whole Blood Or Products (TROOP) Trial1UG3HL157401-01A1 · under PAR-19-329 | HOLCOMB, JOHN BJANSEN, JAN OWANG, HENRY E. | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $1,680,442 | CLTR |
| 2022 | 1/2 percutaneous intervention versus observational trial of arterial ductus in lower gestational age infants (PIVOTAL)1UG3HL161338-01 · under PAR-19-329 | BACKES, CARLSLAUGHTER, JONATHAN LEE | RESEARCH INST NATIONWIDE CHILDREN'S HOSP, OH | $812,264 | ZHL1 |
| 2022 | A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia1UG3HL157564-01A1 · under PAR-19-329 | PULSIPHER, MICHAEL AWILLIAMS, DAVID A | BOSTON CHILDREN'S HOSPITAL, MA | $692,343 | ZHL1 |
| 2021 | 1/2 Pediatric Influence of Cooling duration on Efficacy in Cardiac Arrest Patients (P-ICECAP)1UG3HL159134-01 · under PAR-19-329 | MEURER, WILLIAM JOSEPHMOLER, FRANK WTOPJIAN, ALEXIS A. | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $2,870,887 | CLTR |
| 2021 | 1/2, Clinical Coordinating Center for the Long-term Effectiveness of the Anti-obesity medication Phentermine: the LEAP Trial1UG3HL155801-01A1 · under PAR-19-329 | ARD, JAMY DLEWIS, KRISTINA H | WAKE FOREST UNIVERSITY HEALTH SCIENCES, NC | $1,766,159 | CLTR |
| 2021 | 1/2 Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease (Tele-COPD)1UG3HL155806-01A1 · under PAR-19-329 | BHATT, SURYA P. | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $1,537,067 | CLTR |
| 2021 | 1/2 Doxycycline for Emphysema in People Living with HIV: The DEPTH Trial1UG3HL154944-01A1 · under PAR-19-329 | GLESBY, MARSHALL JKANER, ROBERT J | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $1,432,888 | CLTR |
| 2021 | 1/2 Kids MoD PAH Trial: Mono- vs. Duo-Therapy In Pediatric Pulmonary Arterial Hypertension1UG3HL151458-01A1 · under PAR-19-329 | ABMAN, STEVEN HERBERTBERMAN-ROSENZWEIG, ERIKA S.ROMER, LEWIS H | JOHNS HOPKINS UNIVERSITY, MD | $952,595 | ZHL1 |
| 2021 | (1/2) Randomized Evaluation of Bromocriptine in Myocardial Recovery Therapy for Peripartum Cardiomyopathy (REBIRTH)1UG3HL153847-01A1 · under PAR-19-329 | MCNAMARA, DENNIS M. | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $527,857 | CLTR |
| 2021 | 1/2 The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial1UG3HL152305-01A1 · under PAR-19-329 | COURTNEY, SHERRYFOGLIA, ELIZABETHKIRPALANI, HARESH | UNIVERSITY OF PENNSYLVANIA, PA | $416,018 | CLTR |
| 2020 | 1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis1UG3HL147011-01A1 · under PAR-18-407 | BOECKH, MICHAEL JLIMAYE, ABHIJIT PRAKASHRUBENFELD, GORDON DSTAPLETON, RENEE D | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $2,341,858 | CLTR |
| 2020 | 1/2 Sickel Cell Disease Treatment with Arginine Therapy (STArT Trial)1UG3HL148560-01A1 · under PAR-18-407 | MORRIS, CLAUDIA R | EMORY UNIVERSITY, GA | $1,537,648 | ZHL1 |
| 2020 | 1/2: AZithromycin Therapy in Preschoolers with a Severe Wheezing Episode Diagnosed at the Emergency Department (AZ-SWED)1UG3HL147016-01A1 · under PAR-18-407 | DENNINGHOFF, KURT RMARTINEZ, FERNANDO D | UNIVERSITY OF ARIZONA, AZ | $1,466,425 | ZHL1 |
| 2020 | RACE-CARS CCC 1/21UG3HL146935-01A1 · under PAR-18-407 | GRANGER, CHRISTOPHER B. | DUKE UNIVERSITY, NC | $1,184,044 | CLTR |
| 2020 | (1/2) Log2Lose: Incenting weight loss and dietary self-monitoring in real-time to improve weight management1UG3HL150558-01A1 · under PAR-19-329 | VOILS, CORRINE IONE | UNIVERSITY OF WISCONSIN-MADISON, WI | $1,037,585 | CLTR |
| 2019 | 1/2 ICECAP: Influence of Cooling duration on Efficacy in Cardiac Arrest Patients1UG3HL145269-01A1 · under PAR-18-407 | GEOCADIN, ROMERGRYKOMEURER, WILLIAM JOSEPHSILBERGLEIT, ROBERT | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $4,438,938 | CLTR |
| 2019 | 1/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)1UG3HL143192-01A1 · under PAR-18-407 | GLADWIN, MARK TTRIULZI, DARRELL J | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $1,459,550 | ZHL1 |
| 2019 | 1/1: ARREST RESPIRATORY FAILURE DUE TO PNEUMONIA (ARREST PNEUMONIA)1UG3HL141722-01A1 · under PAR-18-407 | FESTIC, EMIRGAJIC, OGNJENLEVITT, JOSEPH ERICMAHAFFEY, KENNETH W.MATTHAY, MICHAEL A. | STANFORD UNIVERSITY, CA | $1,419,180 | CLTR |
| 2019 | 1/2: An Anesthesia-Centered Bundle to Reduce Postoperative Pulmonary Complications: The PRIME-AIR Study1UG3HL140177-01A1 · under PAR-18-407 | FERNANDEZ-BUSTAMANTE, ANAVIDAL MELO, MARCOS F | MASSACHUSETTS GENERAL HOSPITAL, MA | $1,191,164 | CLTR |
| 2019 | 1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study1UG3HL145266-01A1 · under PAR-18-407 | MARTINEZ, FERNANDO JNOTH, IMRE | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $976,537 | CLTR |
| 2019 | 1/2 Pomalidomide for Bleeding in Patients with Hereditary Hemorrhagic Telangiectasia (HHT)1UG3HL140097-01A1 · under PAR-18-407 | MCCRAE, KEITH R. | CLEVELAND CLINIC LERNER COM-CWRU, OH | $876,052 | CLTR |
| 2019 | 1/2 + PROmote weight loss in obese PAD patients to preVEnt mobility loss: the PROVE Trial1UG3HL141729-01A1 · under PAR-18-407 | MCDERMOTT, MARY MCGRAE | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $599,564 | CLTR |
| 2018 | 1/2 PROSpect: Prone and Oscillation Pediatric Clinical Trial (CCC)1UG3HL141736-01 · under PAR-16-300 | CHEIFETZ, IRA MCURLEY, MARTHA AQKNEYBER, MARTIN | UNIVERSITY OF PENNSYLVANIA, PA | $1,718,755 | ZHL1 |
| 2018 | Impact of Low Flow Nocturnal Oxygen Therapy On Hospital Readmission/Mortalityin Patients with Heart Failure and Central Sleep Apneal (LOFT-HF)1UG3HL140144-01 · under PAR-16-300 | ABRAHAM, WILLIAM TOBER | OHIO STATE UNIVERSITY, OH | $742,108 | CLTR |
| 2018 | Transfusion of Prematurity Early School Age Follow-up (TOP 5) CCC1UG3HL143204-01 · under PAR-16-300 | DEMAURO, SARA BONAMONOPOULOS, PEGGY C | UNIVERSITY OF IOWA, IA | $633,736 | CLTR |
| 2018 | 1/2 A comparison of individualized vs. weight based protocols to treat vaso-occlusive episodes in Sickle Cell Disease (COMPARE VOE)1UG3HL137856-01A1 · under PAR-16-300 | TANABE, PAULA | DUKE UNIVERSITY, NC | $431,577 | CLTR |
| 2018 | 1/2 A randomized controlled trial of pravastatin to prevent preeclampsia in high-risk women1UG3HL140131-01 · under PAR-16-300 | COSTANTINE, MAGEDLAWRENCE CLEARY, KIRSTENSAADE, GEORGE R.WAPNER, RONALD | UNIVERSITY OF TEXAS MED BR GALVESTON, TX | $153,314 | CLTR |
| 2017 | 1/2 CATHETER-DIRECTED THERAPY FOR CHRONIC DVT (C-TRACT TRIAL)1UG3HL138325-01 · under PAR-16-300 | VEDANTHAM, SURESH | WASHINGTON UNIVERSITY, MO | $1,376,983 | CLTR |
| 2017 | 1/2 Hydrocortisone for BPD Respiratory and Developmental Outcomes Study (HYBRiD Outcomes Study): Clinical Coordinating Center1UG3HL137872-01 · under PAR-16-300 | DEMAURO, SARA BONAMOHINTZ, SUSANKALLAPUR, SUHASKIRPALANI, HARESH | CHILDREN'S HOSP OF PHILADELPHIA, PA | $319,407 | CLTR |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.